Literature DB >> 20374225

Self-reported antenatal adherence to medical treatment among pregnant women with Crohn's disease.

M J Nielsen1, M Nørgaard, P Holland-Fisher, L A Christensen.   

Abstract

BACKGROUND: Adherence to medical treatment among women with Crohn's disease (CD) prior to and during pregnancy has never been reported. AIM: To examine both the predictors and prevalence rates of non-adherence to maintenance medical treatment among women with CD prior to and during pregnancy.
METHODS: Among a population of 1.6 million inhabitants, we identified a total of 132 women with CD who had given birth during 2000-2005. Questionnaires were used to investigate predictors and extent of adherence. The validity of self-reported use of medication was assessed using data from the Danish Prescription Database. We used logistic regression to estimate prevalence odds ratios for non-adherence according to smoking status and other predictors.
RESULTS: Eighty percent of the patients returned the questionnaire. A total of 58 (54%) women reported to have been on medical treatment, 50 of whom had fulfilled a prescription on relevant medication. Adherence to medical treatment was 72%. Fear of a negative effect on fertility/foetus was a reason for non-adherence by 18.8% prior to, and by 45.5% during, pregnancy. Among smokers, 30.8% were non-adherent compared with 11.5% among nonsmokers (prevalence odds ratio 3.41, 95% CI 0.8-14.7).
CONCLUSIONS: Despite fear of a negative effect on fertility/foetus, adherence to medical treatment is high in women with CD. There is no substantial variation in adherence prior to and during pregnancy. Smoking prior to pregnancy is a predictor of non-adherence.

Entities:  

Mesh:

Year:  2010        PMID: 20374225     DOI: 10.1111/j.1365-2036.2010.04318.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease.

Authors:  A Abhyankar; M Ham; A C Moss
Journal:  Aliment Pharmacol Ther       Date:  2013-07-15       Impact factor: 8.171

Review 2.  Ethics of studies of drugs in pregnancy.

Authors:  Doreen Matsui
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

Review 3.  Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective.

Authors:  Christian P Selinger; Rupert Wl Leong; Simon Lal
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

4.  Adherence to medication for chronic disorders during pregnancy: results from a multinational study.

Authors:  Angela Lupattelli; Olav Spigset; Hedvig Nordeng
Journal:  Int J Clin Pharm       Date:  2013-10-27

5.  Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease.

Authors:  Amy Yu; Sonia Friedman; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2020-11-19       Impact factor: 5.325

6.  Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society.

Authors:  Christian Selinger; Nicola Carey; Shelley Cassere; Catherine Nelson-Piercy; Aileen Fraser; Veronica Hall; Kate Harding; Jimmy Limdi; Lyn Smith; Marie Smith; Melanie Catherine Gunn; Aarthi Mohan; Khasia Mulgabal; Alexandra Kent; Klaartje Bel Kok; Tracey Glanville
Journal:  Frontline Gastroenterol       Date:  2020-05-07

7.  Adherence with drug therapy in pregnancy.

Authors:  Doreen Matsui
Journal:  Obstet Gynecol Int       Date:  2011-12-26

8.  Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months.

Authors:  Timothy Wen; Adam S Faye; Kate E Lee; Alexander M Friedman; Jason D Wright; Benjamin Lebwohl; Jean-Frederic Colombel
Journal:  Dig Dis Sci       Date:  2021-05-01       Impact factor: 3.487

9.  Positive Predictive Value of Diagnostic Codes for Inflammatory Bowel Disease in the Danish National Patient Registry Among Individuals 50+ Years, Using Patient Records as Reference Standard.

Authors:  Camilla Rye; Katrine Hass Rubin; Frederik Trier Moller; Mette Julsgaard; Tine Jess; Vibeke Andersen
Journal:  Clin Epidemiol       Date:  2021-05-24       Impact factor: 4.790

Review 10.  The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease.

Authors:  Steven Nicolaides; Abhinav Vasudevan; Tony Long; Daniel van Langenberg
Journal:  Intest Res       Date:  2020-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.